Michael J. Farrell - Nov 16, 2023 Form 4/A - Amendment Insider Report for RESMED INC (RMD)

Role
Chief Executive Officer
Signature
Michael J. Farrell, Chief Executive Officer
Stock symbol
RMD
Transactions as of
Nov 16, 2023
Transactions value $
$7,908,732
Form type
4/A - Amendment
Date filed
11/20/2023, 09:14 PM
Date Of Original Report
Nov 20, 2023
Previous filing
Nov 16, 2023
Next filing
Jan 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RMD ResMed Common Stock Options Exercise $200K +3.46K +0.79% $57.76 444K Nov 16, 2023 Direct F1
transaction RMD ResMed Common Stock Tax liability -$200K -1.34K -0.3% $148.90 443K Nov 16, 2023 Direct F2
transaction RMD ResMed Common Stock Tax liability -$350K -2.35K -0.53% $148.94 441K Nov 20, 2023 Direct F3
holding RMD ResMed Common Stock 4.09K Nov 16, 2023 Lisette and Michael Farrell Family Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RMD ResMed Common Stock Options Options Exercise $0 -3.46K -100% $0.00* 0 Nov 16, 2023 ResMed Common Stock 3.46K $57.76 Direct F4
transaction RMD ResMed Common Stock Options Award $8.26M +55.5K $148.90 55.5K Nov 16, 2023 ResMed Common Stock 55.5K $148.90 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Original form amended to include a plan provision auto-exercise prior to option grant expiration.
F2 Disposition to issuer for exercise cost of options auto-exercised under the plan.
F3 Disposition to issuer for tax withholding on vesting of Performance Restricted Stock Units granted on 11/19/2020.
F4 Transaction was a plan auto exercise prior to expiration.
F5 Represents date options first become exercisable. Options vest 1/3 annually each November 11, 2024, 2025, and 2026.